Resource Summary Report

Generated by FDI Lab - SciCrunch.org on Apr 5, 2025

DLD-1

RRID:CVCL_0248
Type: Cell Line

Proper Citation

(RRID:CVCL_0248)

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0248

Proper Citation: (RRID:CVCL_0248)

Sex: Male

Defining Citation: PMID:427742, PMID:2041050, PMID:3335022, PMID:6652615, PMID:7247963, PMID:7621404, PMID:7651727, PMID:7874267, PMID:7972006, PMID:8197130, PMID:8422623, PMID:8464898, PMID:9290701, PMID:9294210, PMID:9515795, PMID:9809040, PMID:10612807, PMID:10674020, PMID:10700188, PMID:11226274, PMID:11414198, PMID:11416159, PMID:11668190, PMID:12068308, PMID:12615714, PMID:16418264, PMID:16854228, PMID:18258742, PMID:19927377, PMID:20570890, PMID:20606684, PMID:22460905, PMID:22490663, PMID:23272949, PMID:24042735, PMID:24755471, PMID:25485619, PMID:25877200, PMID:25841592, PMID:25926053, PMID:25944804, PMID:25960936, PMID:25984343, PMID:26295583, PMID:26537799, PMID:26589293, PMID:28179481, PMID:28192450, PMID:28196595, PMID:28683746, PMID:29101300, PMID:30894373, PMID:31068700, PMID:32172478

Comments: Omics: Transcriptome analysis by RNAseq., Omics: Transcriptome analysis by microarray., Omics: SNP array analysis., Omics: shRNA library screening., Omics: Protein expression by reverse-phase protein arrays., Omics: N-glycan profiling., Omics: miRNA expression profiling., Omics: Deep phosphoproteome analysis., Omics: Deep proteome analysis., Omics: Deep exome analysis., Population: Caucasian., Part of: MD Anderson Cell Lines Project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Part of: AstraZeneca Colorectal cell line (AZCL) panel.

Category: Cancer cell line

Name: DLD-1

Synonyms: DLD 1, DLD1, CoCL3

Cross References: BTO:BTO_0000391, CLO:CLO_0002785, EFO:EFO_0006389, MCCL:MCC:0000138, CLDB:cl1065, CLDB:cl1066, AddexBio:C0009007/36, ArrayExpress:E-MTAB-2706, ATCC:CCL-221, BCRC:60132, BioGRID_ORCS_Cell_line:158, BioSample:SAMN01821551, BioSample:SAMN01821680, BioSample:SAMN03472323, cancercelllines:CVCL_0248, CCRID:1101HUM-PUMC000671, CCRID:3101HUMTCHu134, CCRID:4201HUM-CCTCC00620, Cell_Model_Passport:SIDM00787, ChEMBL-Cells:CHEMBL3307580, ChEMBL-Targets:CHEMBL614285, CLS:300220, ColonAtlas:DLD1, Cosmic:687519, Cosmic:755307, Cosmic:870451, Cosmic:873699, Cosmic:876713, Cosmic:905005, Cosmic:913890, Cosmic:934560, Cosmic:948123, Cosmic:983737, Cosmic:985994, Cosmic:1043810, Cosmic:1066204, Cosmic:1122323, Cosmic:1154643, Cosmic:1175839, Cosmic:1184331, Cosmic:1184082, Cosmic:1187305, Cosmic:1223137, Cosmic:1310949, Cosmic:1466813, Cosmic:1479591, Cosmic:1481418, Cosmic:1519360, Cosmic:1524004, Cosmic:1552176, Cosmic:1571767, Cosmic:1609511, Cosmic:1676737, Cosmic:1805251, Cosmic:2301544, Cosmic:2301972, Cosmic:2389573, Cosmic:2464668, Cosmic:2550352, Cosmic:2646769, Cosmic:2650774, Cosmic:2651870, Cosmic:2664050, Cosmic:2667971, Cosmic:2668249, Cosmic:2727471, Cosmic:2727478, Cosmic:2760067, Cosmic:2787544, Cosmic:2811050, DepMap:ACH-001061, DSMZ:ACC-278, DSMZCellDive:ACC-278, ECACC:90102540, EGA:EGAS00001000610, EGA:EGAS00001002554, ENCODE:ENCBS580BTU, ENCODE:ENCBS621AWM, GEO:GSM206467, GEO:GSM274715, GEO:GSM274716, GEO:GSM274727, GEO:GSM513817, GEO:GSM514291, GEO:GSM741247, GEO:GSM886979, GEO:GSM888048, GEO:GSM1346869, GEO:GSM1374463, GEO:GSM1448161, GEO:GSM1696579, GEO:GSM1696580, GEO:GSM1696581, GEO:GSM1696582, GEO:GSM2549997, IARC_TP53:18, ICLC:HTL95011, JCRB:JCRB9094, KCB:KCB 2011096YJ, KCLB:10221, LINCS_LDP:LCL-1175, Lonza:806, MetaboLights:MTBLS227, PharmacoDB:DLD1_294_2019, PRIDE:PXD000218, PRIDE:PXD001550, PRIDE:PXD005354, PRIDE:PXD005355, RCB:RCB1957, Progenetix:CVCL_0248, PubChem_Cell_line:CVCL_0248, SKY/M-FISH/CGH:1992, SKY/M-FISH/CGH:2763, TKG:TKG 0379, TOKU-E:1078, Wikidata:Q54831148

ID: CVCL_0248

Record Creation Time: 20250131T195347+0000

Record Last Update: 20250131T200149+0000

Ratings and Alerts

No rating or validation information has been found for DLD-1.

Warning: Discontinued: RCB; RCB1957
Omics: Transcriptome analysis by RNAseq., Omics: Transcriptome analysis by microarray., Omics: SNP array analysis., Omics: shRNA library screening., Omics: Protein expression by

reverse-phase protein arrays., Omics: N-glycan profiling., Omics: miRNA expression profiling., Omics: Deep phosphoproteome analysis., Omics: Deep proteome analysis., Omics: Deep exome analysis., Population: Caucasian., Part of: MD Anderson Cell Lines Project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Part of: AstraZeneca Colorectal cell line (AZCL) panel.

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 1372 mentions in open access literature.

Listed below are recent publications. The full list is available at FDI Lab - SciCrunch.org.

Champagne J, et al. (2025) Adoptive T cell therapy targeting an inducible and broadly shared product of aberrant mRNA translation. Immunity, 58(1), 247.

Yong Y, et al. (2025) AMIGO2 characterizes cancer-associated fibroblasts in metastatic colon cancer and induces the release of paracrine active tumorigenic secretomes. The Journal of pathology, 265(1), 14.

Iwata M, et al. (2024) Reduced chemokine C-C motif ligand 1 expression may negatively regulate colorectal cancer progression at liver metastatic sites. Journal of cellular and molecular medicine, 28(7), e18193.

Calbert ML, et al. (2024) 4'-Ethynyl-2'-Deoxycytidine (EdC) Preferentially Targets Lymphoma and Leukemia Subtypes by Inducing Replicative Stress. Molecular cancer therapeutics, 23(5), 683.

Su Y, et al. (2024) HIF-1? Mediates Immunosuppression and Chemoresistance in Colorectal Cancer by Inhibiting CXCL9, -10 and -11. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 173, 116427.

Lonare A, et al. (2024) 14-3-3? restricts YY1 to the cytoplasm, promoting therapy resistance, and tumor progression in colorectal cancer. International journal of cancer.

Li HM, et al. (2024) PHGDH knockdown increases sensitivity to SR1, an aryl hydrocarbon receptor antagonist, in colorectal cancer by activating the autophagy pathway. The FEBS journal.

Tong X, et al. (2024) Potentially functional genetic variants in interferon regulatory factor family genes are associated with colorectal cancer survival. Molecular carcinogenesis, 63(9), 1669.

Ferretti S, et al. (2024) Discovery of WRN inhibitor HRO761 with synthetic lethality in MSI

cancers. Nature, 629(8011), 443.

Teng HW, et al. (2024) CT45A1-mediated MLC2 (MYL9) phosphorylation promotes natural killer cell resistance and outer cell fate in a cell-in-cell structure, potentiating the progression of microsatellite instability-high colorectal cancer. Molecular oncology.

Hayashi K, et al. (2024) Cell-cell contact-dependent secretion of large-extracellular vesicles from EFNBhigh cancer cells accelerates peritoneal dissemination. British journal of cancer, 131(6), 982.

Wu Z, et al. (2024) PD-1 blockade plus COX inhibitors in dMMR metastatic colorectal cancer: Clinical, genomic, and immunologic analyses from the PCOX trial. Med (New York, N.Y.), 5(8), 998.

Kanev PB, et al. (2024) A unified mechanism for PARP inhibitor-induced PARP1 chromatin retention at DNA damage sites in living cells. Cell reports, 43(5), 114234.

Hu M, et al. (2024) Genomic landscape defines peritoneal metastatic pattern and related target of peritoneal metastasis in colorectal cancer. International journal of cancer, 155(7), 1327.

Scelfo A, et al. (2024) Tunable DNMT1 degradation reveals DNMT1/DNMT3B synergy in DNA methylation and genome organization. The Journal of cell biology, 223(4).

Lee S, et al. (2024) B7H6 is the predominant activating ligand driving natural killer cell-mediated killing in patients with liquid tumours: evidence from clinical, in silico, in vitro, and in vivo studies. EBioMedicine, 110, 105459.

Xu SM, et al. (2024) Synergistic anticancer activity of HSP70 and HSF1 inhibitors in colorectal cancer cells: A new strategy for combination therapy. Biochimica et biophysica acta. Molecular basis of disease, 1871(3), 167630.

Jacob J, et al. (2024) Antibody-Drug Conjugates Targeting the EGFR Ligand Epiregulin Elicit Robust Anti-Tumor Activity in Colorectal Cancer. bioRxiv : the preprint server for biology.

Zhu X, et al. (2024) Hypoxia-Responsive CAR-T Cells Exhibit Reduced Exhaustion and Enhanced Efficacy in Solid Tumors. Cancer research, 84(1), 84.

Aoki K, et al. (2024) NELF and PAF1C complexes are core transcriptional machineries controlling colon cancer stemness. Oncogene, 43(8), 566.